Peer-reviewedCC BY-NC-NDLancet Oncology
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial
Related
- Real‐World Overall Survival With Abiraterone Acetate and Enzalutamide in Patients With Chemotherapy‐Naïve Metastatic Castration‐Resistant Prostate Cancer From the Flatiron Electronic Health Records Database
- Baseline serum carcinoembryonic antigen (CEA) is an independent prognostic biomarker for metastatic castration-resistant prostate cancer (mCRPC) patients receiving 177Lu-PSMA therapy
- Prognostic Value of Baseline High-Uptake PSMA Tumor Volume Fraction in Metastatic Castration-Resistant Prostate Cancer Patients Treated with [177Lu]Lu-PSMA Radioligand Therapy
- Dynamics of circulating tumor cell subsets defined by PSMA and EpCAM predict survival in metastatic castration-resistant prostate cancer patients treated with 177Lu-PSMA-617
- Immune biomarkers of response and resistance to ipilimumab and nivolumab in metastatic castration-resistant prostate cancer
BibTeX
@article{smith2026niraparib,
title = {{Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial}},
author = {Matthew Smith and Howard Scher and Shahneen Sandhu and Eleni Efstathiou and Primo Lara and Evan Yu and Daniel George and Kim Chi and Fred Saad and Olof Ståhl and David Olmos and Daniel Danila and Gary Mason and Byron Espina and Xin Zhao and Karen Urtishak and Peter Francis and Angela Lopez-Gitlitz and Karim Fizazi and Francis Parnis and Anthony Joshua and Lisa Horvath and Christopher Steer and Gavin Marx and Shahneen Sandhu and Howard Gurney and Thomas Ferguson and Siska van Bruwaene and Daisy Luyten and Peter Schatteman and Nicolaas Lumen and Luc Dirix and Jean-Charles Goeminne and Thierry Gil and Emmanuel Seront and Christof Vulsteke and Celio Kussumoto and Fabio Franke and Fabricio Augusto Martinelli de Oliveira and Andrea Juliana Pereira de Santana Gomes and Hélio Pinczowski and Daniel d'Almeida Preto and Luis Eduardo Zucca and Giuliano Santos Borges and Andre Murad and Fred Saad and Kim Chi and Yves Fradet and Neil Fleshner and Urban Emmenegger and Klaus Brasso and Karim Fizazi and Stephane Culine and Antoine Thiery-Vuillemin and Florence Joly and Aude Fléchon and Werner Hilgers and Jean-Christophe Eymard and Delphine Borchiellini and Philippe Barthélémy},
journal = {Lancet Oncology},
year = {2026},
month = sep,
doi = {10.1016/s1470-2045(21)00757-9},
url = {https://hal.science/hal-05744050v1},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial
AU - Matthew Smith
AU - Howard Scher
AU - Shahneen Sandhu
AU - Eleni Efstathiou
AU - Primo Lara
AU - Evan Yu
AU - Daniel George
AU - Kim Chi
AU - Fred Saad
AU - Olof Ståhl
AU - David Olmos
AU - Daniel Danila
AU - Gary Mason
AU - Byron Espina
AU - Xin Zhao
AU - Karen Urtishak
AU - Peter Francis
AU - Angela Lopez-Gitlitz
AU - Karim Fizazi
AU - Francis Parnis
AU - Anthony Joshua
AU - Lisa Horvath
AU - Christopher Steer
AU - Gavin Marx
AU - Shahneen Sandhu
AU - Howard Gurney
AU - Thomas Ferguson
AU - Siska van Bruwaene
AU - Daisy Luyten
AU - Peter Schatteman
AU - Nicolaas Lumen
AU - Luc Dirix
AU - Jean-Charles Goeminne
AU - Thierry Gil
AU - Emmanuel Seront
AU - Christof Vulsteke
AU - Celio Kussumoto
AU - Fabio Franke
AU - Fabricio Augusto Martinelli de Oliveira
AU - Andrea Juliana Pereira de Santana Gomes
AU - Hélio Pinczowski
AU - Daniel d'Almeida Preto
AU - Luis Eduardo Zucca
AU - Giuliano Santos Borges
AU - Andre Murad
AU - Fred Saad
AU - Kim Chi
AU - Yves Fradet
AU - Neil Fleshner
AU - Urban Emmenegger
AU - Klaus Brasso
AU - Karim Fizazi
AU - Stephane Culine
AU - Antoine Thiery-Vuillemin
AU - Florence Joly
AU - Aude Fléchon
AU - Werner Hilgers
AU - Jean-Christophe Eymard
AU - Delphine Borchiellini
AU - Philippe Barthélémy
PY - 2026
DA - 2026/09/09
JO - Lancet Oncology
DO - 10.1016/s1470-2045(21)00757-9
UR - https://hal.science/hal-05744050v1
SN - 1470-2045
SN - 1474-5488
ER -